Lazarus Howard 4

What Happened Lazarus Howard, Chief Medical Officer of Avalyn Pharma (AVLN), was granted 211,975 derivative shares on April 29, 2026 at no cash cost (reported as an "A" — award/grant). The award is reported as a derivative security (acquired at $0.00) and is subject to a service-based vesting schedule outlined in the filing.

Key Details

• Transaction date: 2026-04-29; reported on Form 4 filed 2026-05-01 (timely filing).
• Instrument: Award/grant of 211,975 derivative shares at $0.00 (transaction code A).
• Vesting: 25% of the shares underlying the award vested on September 12, 2025; the remaining 75% vest in 36 equal monthly installments thereafter, contingent on continued service (footnote in filing).
• Shares owned after transaction: Not specified in the Form 4.
• No sale, exercise, or tax-withholding event reported in this filing.

Context This filing records a compensation-related equity award rather than an open-market purchase or sale. Such grants are common for executives as part of compensation and do not by themselves indicate immediate buying or selling of stock; vesting ties future ownership to continued service.